Your browser doesn't support javascript.
loading
Chimeric Antigen Receptor-T Cell Therapy / 대한내과학회지
Korean Journal of Medicine ; : 229-237, 2022.
Article in Korean | WPRIM | ID: wpr-938673
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
Full text: Available Index: WPRIM (Western Pacific) Language: Korean Journal: Korean Journal of Medicine Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Korean Journal: Korean Journal of Medicine Year: 2022 Type: Article